Stephen O. Andersen protecting the stratospheric ozone layer. At EPA he rose to Deputy Director for Stratospheric Ozone Protection and then transferred to the Climate Protection Partnerships Division, where he was Director of Strategic Climate Projects until his retirement from government in 2009. The timing of Andersen’s arrival at EPA was fortuitous. 1987 proved to be a watershed moment in the effort to stop ozone depletion, which increased risks of skin cancer and threatened to wipe out crops and ecosystems, among many adverse impacts. The Montreal Protocol on Substances that Deplete the Ozone Layer was agreed on 16 September 1987 and created a
Wiley protocol at separate times throughout the period. The protocol is promoted as differing from conventional hormone replacement therapy in several ways: The protocol also includes a follow-up program to monitor the serum of the bioidentical hormones. Wiley has stated that in her opinion, the most important aspect of the protocol is the specific schedule and levels of the hormone doses rather than their bioidentical nature. A patent was granted for the protocol in 2011 for the specific blend of hormones and dosing method. Concerns have been raised that serum levels may not be an acceptable marker for transdermally administered hormones, that